Sean Flynn Sells 15,000 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $45.64, for a total transaction of $684,600.00. Following the completion of the transaction, the insider directly owned 1,647 shares of the company’s stock, valued at approximately $75,169.08. This trade represents a 90.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Vericel Price Performance

Shares of VCEL stock traded down $0.58 during midday trading on Tuesday, reaching $44.49. 743,265 shares of the company traded hands, compared to its average volume of 621,141. The firm’s 50 day simple moving average is $36.33 and its two-hundred day simple moving average is $35.85. Vericel Corporation has a 1-year low of $28.95 and a 1-year high of $46.62. The firm has a market cap of $2.27 billion, a PE ratio of 105.93 and a beta of 1.12.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The business had revenue of $68.43 million for the quarter, compared to analyst estimates of $63.68 million. During the same quarter in the previous year, the company earned ($0.23) EPS. The company’s quarterly revenue was up 30.1% on a year-over-year basis. As a group, research analysts anticipate that Vericel Corporation will post 0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vericel

Large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in shares of Vericel in the fourth quarter worth $27,000. Huntington National Bank boosted its stake in shares of Vericel by 51.3% during the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 273 shares during the last quarter. Quarry LP purchased a new stake in Vericel during the 4th quarter worth about $31,000. Farther Finance Advisors LLC increased its position in Vericel by 116.5% during the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 522 shares in the last quarter. Finally, Truvestments Capital LLC raised its stake in Vericel by 175.4% in the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 977 shares during the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on VCEL. HC Wainwright reissued a “buy” rating and issued a $64.00 target price on shares of Vericel in a report on Friday, May 8th. Leerink Partners reaffirmed an “outperform” rating and set a $46.00 price target on shares of Vericel in a research note on Tuesday, March 10th. Truist Financial decreased their price objective on shares of Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. Finally, Weiss Ratings upgraded shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $52.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.